ZYBTNasdaqPharmaceutical Preparations
Zhengye Biotechnology Holding Ltd
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 28, 2026
$1.45+0.05 (+3.57%)
Close on Oct 19, 2026
Margins
Share of revenue, fiscal years 2021 to 2025
Gross margin
20.5%
Operating margin
-60.6%
Net margin
-60.0%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -37.6% | -23.5% | – | – | |
| Gross profit | -73.9% | -45.6% | – | – | |
| Free cash flow | -55.1% | – | – | – |
Returns and balance sheet
5 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2021 | FY2021 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | -26.1% | |
| Return on assets | – | – | -15.0% | |
| Current ratio | – | – | 1.14 | |
| Debt to equity | – | – | – | |
| Net debt to EBITDA | – | – | – | |
| Interest coverage | – | – | -20.7× | |
| Inventory turnover | – | – | 1.9× | |
| Capex to revenue | – | – | 0.9% | |
| Diluted shares | – | – | 47M |
Cash use needs five years of cash flow figures
Zhengye Biotechnology does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-60.0%
×Asset turnover0.25×
×Equity multiplier1.74×
=Return on equity, FY2025-26.1%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -60.0% | 0.25× | 1.74× | -26.1% |
| FY2024 | 6.1% | 0.38× | 1.78× | 4.1% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-CN¥69.78M
- Cash generatingOperating cash flow above zeroCN¥13.33M
- Return on assets improvedROA up on the prior year2.3% → -14.1%
- Earnings backed by cashOperating cash flow above net incomeCN¥13.33M vs -CN¥69.78M
- Less leverageLong-term debt to assets fell1.0% → –
- Better liquidityCurrent ratio rose1.31 → 1.14
- No dilutionShare count did not rise46M → 47M
- Gross margin improvedGross margin up on the prior year48.99% → 20.51%
- More efficientAsset turnover rose0.37 → 0.24